Background and objectives: This pilot study measures the response of women with stress incontinence, overactive bladder, lubrication and sexual dysfunction (libido, arousal, dyspareunia) to evaluate the safety, tolerability and clinical efficacy of "O-Shot" Platelets Rich Plasma (PRP) of the vulvo vaginal field. PRP has recently been shown to accelerate rejuvenate aging skin by various growth factors and cell molecular adhesions. Each patient received two sessions at the intervals of two months apart.
Introduction
Platelet Rich Plasma (PRP) has been used over last 20 years as an e ective treatment in various medical and surgical elds [1] . Н ere are publications about the use of PRP in wound treatment, maxillofacial surgery, soі tissue injuries, orthopedic, gastrointestinal surgeries, burns, and in cosmetic procedures [1, 2] . PRP has been demonstrated to be e ective with no serious side e ects and activates pluripotent cells in the area of injection resulting in rejuvenation [3, 4] .
Since PRP is autologous, there are no known contraindications and also o ers the advantage of owing into tissue. Н ere are several growth factors and cytokines [5, 6] in the platelets that are released to cellular damage starting to work together stimulating process of broblast collagen synthesis. Н is pilot study measures the responses of women with stress incontinence, overactive bladder, varying degrees of sexual dysfunction (libido, orgasm, and dyspareunia) and lack lubrication.
Material and Methods
About 68 non-selected women, ages 32-97 (average: 62.8 years old) G 60/Para 48/Abortation 27 were enrolled in this pilot study from August 1 st 2016 to February 1 st 2017 with complaints of urinary problems such as urinary stress incontinence, overactive bladder (OAB), lack of lubrication and sexual dysfunction (lack of libido, decreased arousal, dyspareunia and anorgasmy) ( Table 1 ).
All sixty-eight women were treated by the author and underwent to have a Platelet Rich Plasma "O-Shot" (Dr. Charles Runels Patent) as proposal protocol treatment getting two session two months apart.
All patients work up: Cure to urinary complaints was de ned as complete subjective relief of urinary incontinence (stress/overactive bladder) and absence of loss urine on physical examination. Н ose complaints of lack of lubrication and sexual dysfunction a subjective improvement of their symptoms and a questionnaire answered were used as a treatment response.
Symptoms
Patients 
Technique
Peripheral blood was drawn from the arm (Figure 3 ) and a numbing cream Benzocaine 20%; Lidocaine 6%; Tetracaine 4% was used in the vulvo vaginal area. Aі er isolation of the PRP, 10% of calcium chloride 0.2 cc is added to the 4 cc of PRP ( Figure 5 ) and injected by a 5 cc syringe with 30 G ½ needle into the following anatomic areas: 2 cc in Pubocervical fascia (G-Spot); 0.5 cc in Skene's gland each and 1 cc in to the clitoral area (button part of the clitoris) ( Figure 6 ). 
Results
About sixty-eight women were treated by PRP ("O-Shot" 2 sessions, 2 months apart) in the rst non-randomized pilot study in the Southern Brazil, from August 1 st 2016 to February 1 st 2017 in a private clinic, in Porto Alegre, RS-Brazil. Around 94% (64 patients) were satis ed with the outcome reporting subjectively and by a questionnaire improvement of lubrication and sexual dysfunction (arousal, libido, dyspareunia and anorgasmy) on the rst session and getting better aі er the second PRP Shot. Н ose complaints stress urinary stress urinary incontinence (13 patients) reported more than 90% of relief of the symptoms. It was amazing and surprising that these patients related great deal of bene ts aі er 2 weeks of the rst "O-Shot". Patients with overactive bladder (15 patients) had 74% of relief of symptoms and 6% (4 patients) have no treatment response. All females with mixed urinary incontinence (22 patients) were satis ed with the results. Cure was de ned (urinary problems: stress incontinence, overactive bladder and mixed incontinence) as complete subjective relief of urinary incontinence, questionnaire and absence of loss urine on physical examination.
Side-e ects
We have no extreme sexual arousal or ejaculating problem. None of our patients were lost within the 6 month follow up period, and the procedure was well tolerated without serious side e ects. Burning sensation were exposed by 100% of our patients when injection in para urethral areas and clitoris.
Discussion
Н e use of Platelet Rich Plasma (PRP) has been known in aesthetic medicine. PRP is an autologous preparation of platelets in concentrated plasma that contains a mixture of bioactive agents derived from both platelet and plasma. When PRP is activated (calcium chloride), and injected in to the anatomic areas such as clitoris; pubo-cervical fascia; G spot; Skene's glands, then growth factors may cause di erentiation of pluripotent stem cells resulting in neo-angiogenesis, broblast growth, and neuronal growth, improving physiologic responsiveness. PRP is non-antigenic and contains no synthesis agents that could cause an untoward local or systemic reaction. We could nd no reports of granuloma formation, infections, or local tissue necrosis. Н e body will not react to it immunologically [7] . No allergic reactions. PRP induces regrowth of new tissues by of the activation of pluripotent stem cells. [7, 8] Improved vascularity and neuronal regrowth in the vagina and in the clitoral area could restore or possibly enhance sexual responsiveness and sensitivity by increasing blood ow. Collagen and sensory nerve regrowth might relieve coital discomfort as well as enhance vaginal sensitivity. It is a great bene t to those su ering with stress incontinence and overactive bladder, rejuvenating the entire surrounding area to the urethra, pubo-cervical fascia and Skene's glands. It seems to last around 1-2 years.
Conclusion
Platelet Rich Plasma is a safe non-surgical, cost-e ective procedure to be utilized as a new tool to help patients with stress incontinence, overactive bladder and sexual dysfunctions.
